Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QEL-002
- Development stage
- Preclinical
- Lead developer
- Quell Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
QEL-002 is an engineered T-regulatory (Treg) cell therapy developed by Quell Therapeutics for the treatment of type 1 diabetes. It is a chimeric antigen receptor regulatory T cell (CAR-Treg) therapy designed to target and suppress the autoimmune response against pancreatic islet cells in early onset type 1 diabetes, aiming to prevent further beta cell loss, control dysglycemia, and reduce or eliminate the need for exogenous insulin. The drug functions as a regulatory T-lymphocyte replacement, leveraging immunologic cytotoxicity and immune modulation to restore immune tolerance in patients with type 1 diabetes[1][2][4].
Beyond the preview
Go deeper on QEL-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QEL-002.